Company intelligence / Profile preview
Tonix Pharmaceuticals
- Ownership
- Public · TNXP
- Employees
- ~103
- Development stage
- NDA
Overview
Tonix has submitted an NDA for TNX-102 SL for fibromyalgia with a PDUFA date of August 15, 2025. The company reported positive Phase 1 results for TNX-1500, their anti-CD40L mAb for kidney transplant rejection prevention. They also have a contract with the U.S. DoD's DTRA for up to $34 million to develop TNX-4200.
- Therapeutic areas
- PsychiatryRheumatologyImmunologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small moleculesBiologicsVaccinesMonoclonal antibodies
- Industry
- Biotech
Drug pipeline
46 assets45 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $195.8M
- Total revenue
- $13.5M
- Enterprise value
- $20.8M
Beyond the preview
Go deeper on Tonix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tonix Pharmaceuticals.